S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
This Little Known Automaker May Save Your Life and Your Portfolio
US consumer confidence tumbles in September as American anxiety about the future grows
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Pain for Gain: 2 Stocks Whose CEOs Left Without a Clue
3 Household Names With RSIs That Scream Oversold
NASDAQ:POAI

Predictive Oncology (POAI) Stock Forecast, Price & News

$3.16
+0.04 (+1.28%)
(As of 09/26/2023 ET)
Compare
Today's Range
$3.05
$3.21
50-Day Range
$2.96
$6.21
52-Week Range
$2.47
$13.88
Volume
9,926 shs
Average Volume
25,989 shs
Market Capitalization
$12.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

POAI stock logo

About Predictive Oncology (NASDAQ:POAI) Stock

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

POAI Price History

POAI Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Predictive Oncology moves company headquarters to Pittsburgh
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
Predictive Oncology Announces Reverse Stock Split
See More Headlines
Receive POAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter.

POAI Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:POAI
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-25,740,000.00
Net Margins
-1,246.52%
Pretax Margin
-1,246.52%

Debt

Sales & Book Value

Annual Sales
$1.51 million
Book Value
$5.53 per share

Miscellaneous

Free Float
3,937,000
Market Cap
$12.73 million
Optionable
Not Optionable
Beta
1.54
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Raymond F. Vennare (Age 70)
    CEO & Chairman
    Comp: $581.58k
  • Mr. Robert L. Myers M.B.A. (Age 68)
    CFO & Sec.
    Comp: $511.87k
  • Ms. Theresa Ferguson
    Sr. Director of Marketing
  • Dr. Pamela Bush M.B.A. (Age 49)
    Ph.D., Chief Bus. Officer
  • Dr. Lawrence J. DeLucas D.Sc
    O.D, Ph.D., Sr. VP of Biologics
  • Dr. Arlette H. Uihlein FCAP
    M.D., Sr. VP of Translational Medicine & Drug Discovery and Medical Director













POAI Stock - Frequently Asked Questions

How have POAI shares performed in 2023?

Predictive Oncology's stock was trading at $6.1320 on January 1st, 2023. Since then, POAI stock has decreased by 48.5% and is now trading at $3.16.
View the best growth stocks for 2023 here
.

When is Predictive Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our POAI earnings forecast
.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings results on Thursday, August, 10th. The medical instruments supplier reported ($0.95) earnings per share for the quarter. The medical instruments supplier had revenue of $0.49 million for the quarter. Predictive Oncology had a negative net margin of 1,246.52% and a negative trailing twelve-month return on equity of 90.72%.

When did Predictive Oncology's stock split?

Predictive Oncology shares reverse split on the morning of Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Predictive Oncology investors own include NVIDIA (NVDA), OPKO Health (OPK), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Overstock.com (OSTK), Riot Platforms (RIOT), AcelRx Pharmaceuticals (ACRX), Boeing (BA), QUALCOMM (QCOM) and Sorrento Therapeutics (SRNE).

What is Predictive Oncology's stock symbol?

Predictive Oncology trades on the NASDAQ under the ticker symbol "POAI."

Who are Predictive Oncology's major shareholders?

Predictive Oncology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.81%), RB Capital Management LLC (0.52%), Renaissance Technologies LLC (0.48%), State Street Corp (0.30%) and Carnegie Mellon University (0.26%). Insiders that own company stock include Carl I Schwartz, Charles Lee Sr Nuzum Sr, Daniel E Handley, J Melville Engle, Raymond F Vennare and Robert L Myers.
View institutional ownership trends
.

How do I buy shares of Predictive Oncology?

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Predictive Oncology's stock price today?

One share of POAI stock can currently be purchased for approximately $3.16.

How much money does Predictive Oncology make?

Predictive Oncology (NASDAQ:POAI) has a market capitalization of $12.73 million and generates $1.51 million in revenue each year. The medical instruments supplier earns $-25,740,000.00 in net income (profit) each year or ($4.84) on an earnings per share basis.

How can I contact Predictive Oncology?

Predictive Oncology's mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The official website for the company is www.precisiontherapeutics.com. The medical instruments supplier can be reached via phone at (651) 389-4800 or via email at james@haydenir.com.

This page (NASDAQ:POAI) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -